About 10x genomics - TXG
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics. The company’s products include Single Cell Gene Expression, Immune Profiling, ATAC, and Genome. The company was founded by Serge Saxonov, Ben Hindson and Kevin D. Ness on July 2, 2012 and is headquartered in Pleasanton, CA.
TXG At a Glance
10X Genomics, Inc.
6230 Stoneridge Mall Road
Pleasanton, California 94588
| Phone | 1-925-401-7300 | Revenue | 642.82M | |
| Industry | Biotechnology | Net Income | -43,544,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 5.245% | |
| Fiscal Year-end | 12 / 2026 | Employees | 1,178 | |
| View SEC Filings |
TXG Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 3.165 |
| Price to Book Ratio | 2.615 |
| Price to Cash Flow Ratio | 14.96 |
| Enterprise Value to EBITDA | -28.302 |
| Enterprise Value to Sales | 2.482 |
| Total Debt to Enterprise Value | 0.053 |
TXG Efficiency
| Revenue/Employee | 545,690.153 |
| Income Per Employee | -36,964.346 |
| Receivables Turnover | 7.792 |
| Total Asset Turnover | 0.656 |
TXG Liquidity
| Current Ratio | 4.46 |
| Quick Ratio | 4.093 |
| Cash Ratio | 3.411 |
TXG Profitability
| Gross Margin | 70.385 |
| Operating Margin | -15.587 |
| Pretax Margin | -6.208 |
| Net Margin | -6.774 |
| Return on Assets | -4.443 |
| Return on Equity | -5.781 |
| Return on Total Capital | -4.944 |
| Return on Invested Capital | -5.268 |
TXG Capital Structure
| Total Debt to Total Equity | 10.594 |
| Total Debt to Total Capital | 9.579 |
| Total Debt to Total Assets | 8.101 |
| Long-Term Debt to Equity | 9.214 |
| Long-Term Debt to Total Capital | 8.332 |